InvestorsHub Logo
Followers 0
Posts 1151
Boards Moderated 0
Alias Born 07/10/2003

Re: None

Saturday, 07/26/2003 9:17:46 PM

Saturday, July 26, 2003 9:17:46 PM

Post# of 82595
It looks like Lonnie Bookbinder PH.D worked at RIBI Immunochem it also looks like Corixa wanted to buy out RIBI at one time but RIBI turned them down.

Heres a little info. on RIBI -

Ribi ImmunoChem Research, Inc. develops biopharmaceutical products that stimulate the immune system to generate natural agents and signals to prevent and treat human diseases. The company researches, develops, produces and markets these products some of which are under investigation by other companies for use as adjuvants. The company also manufactures clinical products and develops processes for the commercial scale production of its compounds. The company's technology is based on potent capacities of certain microbial products to modulate the cytokine cascade in man and other animals. The product development of the company is the use of MPL immunomodulator in combination with other immunomodulator. The company's product, human biopharmaceutical is being regulated by the FDA, which requires to be tested for the use of human treatment. The company has 20 research products to date. The company has been using its research products to develop immunotherapeutic agents for the treatment of malignant tumors and other diseases. The company has spent approximately $237,000 towards year 2000 expenses. Contracts & licences accounted for 53% of 1998 revenues & biopharmaceutical products, 47%.